Gadolinium MRI contrast agents in patients with severe renal insufficiency : are they safe?

dc.contributor.author	Darwish, Tarek	eng
dc.date.issued	2009-03	eng
dc.description.abstract	Iodine contrast nephropathy is the third most common cause of hospital-acquired acute renal failure. With the increasing number of diagnostic and interventional procedures, gadolinium-based contrast agents (approved by the FDA in 1988) have been considered a safe, non-nephrotoxic alternative.	eng
dc.description.bibref	Includes bibliographical references	eng
dc.format.extent	2 pages : illustrations	eng
dc.identifier.uri	https://hdl.handle.net/10355/61734
dc.language	English	eng
dc.publisher	University of Missouri, Department of Medicine, Division of Hospital Medicine	eng
dc.relation.ispartof	Missouri hospitalist, issue 15 (2009 March 25)	eng
dc.rights	OpenAccess.	eng
dc.rights.license	This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.
dc.source	Harvested from the American Journal of Hospital Medicine website (http://medicine2.missouri.edu/jahm/) in 2018.	eng
dc.subject	iodine contrast, hospital-acquired acute renal failure, gadolinium-based contrast agents, nephrogenic systemic fibrosis, renal dysfunction	eng
dc.title	Gadolinium MRI contrast agents in patients with severe renal insufficiency : are they safe?	eng
dc.type	Article	eng